Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
Total Valuation
Unicycive Therapeutics has a market cap or net worth of $168.59M. The enterprise value is $109.54M.
Market Cap$168.59M
Enterprise Value$109.54M
Share Statistics
Unicycive Therapeutics has 25,237,782 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,237,782
Owned by Insiders21.10%
Owned by Institutions25.54%
Financial Efficiency
Unicycive Therapeutics’s return on equity (ROE) is -0.88 and return on invested capital (ROIC) is -97.37%.
Return on Equity (ROE)-0.88
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-97.37%
Return on Capital Employed (ROCE)-0.98
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count22
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Unicycive Therapeutics is ―. Unicycive Therapeutics’s PEG ratio is 0.49.
PE Ratio―
PS Ratio0.00
PB Ratio30.36
Price to Fair Value30.36
Price to FCF-29.25
Price to Operating Cash Flow-33.89
PEG Ratio0.49
Income Statement
In the last 12 months, Unicycive Therapeutics had revenue of 0.00 and earned -26.55M in profits. Earnings per share was -1.67.
Revenue0.00
Gross Profit0.00
Operating Income-29.52M
Pretax Income-26.55M
Net Income-26.55M
EBITDA-25.91M
Earnings Per Share (EPS)-1.67
Cash Flow
In the last 12 months, operating cash flow was -31.32M and capital expenditures -24.00K, giving a free cash flow of -31.34M billion.
Operating Cash Flow-31.32M
Free Cash Flow-31.34M
Free Cash Flow per Share-1.24
Dividends & Yields
Unicycive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.74
52-Week Price Change25.98%
50-Day Moving Average6.67
200-Day Moving Average5.46
Relative Strength Index (RSI)49.77
Average Volume (3m)493.25K
Important Dates
Unicycive Therapeutics upcoming earnings date is May 19, 2026, Before Open (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Unicycive Therapeutics as a current ratio of 2.59, with Debt / Equity ratio of 0.39%
Current Ratio2.59
Quick Ratio2.59
Debt to Market Cap<0.01
Net Debt to EBITDA1.12
Interest Coverage Ratio-415.73
Taxes
In the past 12 months, Unicycive Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Unicycive Therapeutics EV to EBITDA ratio is -34.25, with an EV/FCF ratio of -28.32.
EV to Sales0.00
EV to EBITDA-34.25
EV to Free Cash Flow-28.32
EV to Operating Cash Flow-28.34
Balance Sheet
Unicycive Therapeutics has $41.27M in cash and marketable securities with $117.00K in debt, giving a net cash position of $41.15M billion.
Cash & Marketable Securities$41.27M
Total Debt$117.00K
Net Cash$41.15M
Net Cash Per Share$1.63
Tangible Book Value Per Share$0.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Unicycive Therapeutics is $49.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$49.83
Price Target Upside645.96% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast66.05%